垂体腺瘤的TS分期(附631例疗效分析)

Clinical Staging of Pituitary Tumors (TS Staging System) ——An Analysis of Therapeutic Results of 631 Cases

目的 :在临床实践中对垂体腺瘤进行分期 ,并以指导临床治疗。方法 :依据肿瘤的大小及患者内分泌情况进行分期 ,以T表示肿瘤的大小 ,S表示内分泌紊乱的程度 ,临床分期 :Ⅰ期T1S1;Ⅱ期T2 S1;Ⅲ期T3S1;Ⅳ期T4 S1、T1～ 4 S2 。结果 :分析了自 1975～ 1990年收治的 6 31例垂体瘤患者 ,控制率为 :Ⅰ期 94.7% ,Ⅱ期 92 .9% ,Ⅲ期84.6 % ,Ⅳ期 6 3 .3%。经统计学处理 :Ⅰ期、Ⅱ期与Ⅲ期间 ,Ⅰ期、Ⅱ期与Ⅳ期 ,Ⅲ期与Ⅳ期间疗效有差异(P <0 .0 5 )。结论 :TS分期可预示垂体瘤患者的预后 。

Objective:To evaluate the importance of clinical staging of pituitary adenoma in guiding the clinical therapeutic regimen.Methods: From January 1975 to December 1990, six hundred and thirty-one patients with a clinical and histological diagnosis of pituitary adenoma were treated by radiotherapy with or without surgery. All the patients were staged by ST staging system (T means the size of tumor and S means the degree of endocrinal imbalance). The clinical staging: StageⅠ:T 1S 1; StageⅡ:T 2S 1; StageⅢ:T 3S 1; StageⅣ:T 1～3 S 2 or T 4S 1～2 .Results: Control effect rate: Stage I 94.6%, Stage II 91.2%, Stage III 84.5%, Stage IV 63.3%. The therapeutic effects showed that the differences between Stage I, Stage II and Stage III; Stage I, Stage II and Stage IV; Stage III and Stage IV had statistical significance ( P <0.05).Conclusion: It is thought that TS Staging System can predict the prognosis of pituitary adenoma and it can be used to guide the variant regimen for different stage patients.